Mineralocorticoid and Angiotensin Receptor Antagonism During Hyperaldosteronemia
- 1 August 2002
- journal article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 40 (2) , 124-129
Abstract
Elevated aldosterone levels induce a spironolactone-inhibitable decrease in cardiac sarcolemmal Na + -K + pump function. Because pump inhibition has been shown to contribute to myocyte hypertrophy, restoration of Na + -K + pump function may represent a possible mechanism for the cardioprotective action of mineralocorticoid receptor (MR) blockade. The present study examines whether treatment with the angiotensin type 1 receptor antagonist losartan, with either spironolactone or eplerenone, has additive effects on sarcolemmal Na + -K + pump activity in hyperaldosteronemia. New Zealand White rabbits were divided into 7 different groups: controls, aldosterone alone, aldosterone plus spironolactone, aldosterone plus eplerenone, aldosterone plus losartan, aldosterone plus losartan and spironolactone, and aldosterone plus losartan and eplerenone. After 7 days, myocytes were isolated by enzymatic digestion. Electrogenic Na + -K + pump current (I p ), arising from the 3:2 Na + :K + exchange ratio, was measured by the whole-cell patch clamp technique. Elevated aldosterone levels lowered I p ; treatment with losartan reversed aldosterone-induced reduced pump function, as did MR blockade. Coadministration of spironolactone or eplerenone with losartan enhanced the losartan effect on pump function to a level similar to that measured in rabbits given losartan alone in the absence of hyperaldosteronemia. In conclusion, hyperaldosteronemia induces a decrease in I p at near physiological levels of intracellular Na + concentration. Treatment with losartan reverses this aldosterone-induced decrease in pump function, and coadministration with MR antagonists produces an additive effect on pump function, consistent with a beneficial effect of MR blockade in patients with hypertension and congestive heart failure treated with angiotensin type 1 receptor antagonists.Keywords
This publication has 33 references indexed in Scilit:
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Differential Regulation of Na/K-ATPaseα-subunit Isoform Gene Expressions in Cardiac Myocytes by Ouabain and Other Hypertrophic StimuliJournal of Molecular and Cellular Cardiology, 1997
- Modulation of Cytosolic Protein Kinase C and Calcium Ion Activity by Steroid Hormones in Rat Distal ColonJournal of Biological Chemistry, 1996
- Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failureJournal of Cardiac Failure, 1996
- Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery diseaseThe American Journal of Cardiology, 1995
- Rapid Aldosterone Signaling in Vascular Smooth-Muscle Cells - Involvement of Phospholipase-C, Diacylglycerol and Protein-Kinase-C-αBiochemical and Biophysical Research Communications, 1995
- ?Escape? of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapyCardiovascular Drugs and Therapy, 1995
- Sodium pump current measured in cardiac ventricular myocytes isolated from control and potassium depleted rabbitsCardiovascular Research, 1994
- Effect of aldosterone on vascular angiotensin II receptors in the ratCanadian Journal of Physiology and Pharmacology, 1985
- K+-dependent 3-O-methylfluorescein phosphatase activity in crude homogenate of rodent heart ventricle: Effect of K+ depletion and changes in thyroid statusEuropean Journal of Pharmacology, 1985